Fenofibrate or Gemfibrozil for Treatment of Types IIa and IIb Primary Hyperlipoproteinemia: A Randomized, Double-Blind, Crossover Study

Insua, A.; Massari, Fabio; Moncalvo, Juan José Rodríguez; Zanchetta, José R.; Insua, Ana María

doi:10.4158/ep.8.2.96

Cited by 34 publications

(21 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It decreases the serum level of cholesterol, and triglycerides and increases the level of high-density lipoprotein (HDL) [1][2][3]. Fenofibrate, like other fibrates, limits the availability of fatty acids for triglyceride synthesis within the liver.…”

Section: Introductionmentioning

confidence: 99%

Fenofibrate and fenofibric acid analysis by capillary electrophoresis

Shihabi

2004

Electrophoresis

View full text Add to dashboard Cite

A capillary electrophoresis method has been developed to measure fenofibrate in capsules based on micellar electrokinetic capillary chromatography with detection at 280 nm using a borate buffer containing sodium dodecyl sulfate (SDS). However, the metabolite of this drug (fenofibric acid) in serum and whole blood was analyzed by capillary zone electrophoresis (CZE) in a borate-carbonate buffer using acetonitrile stacking. The analysis is rapid, < 7 min with no interferences. Incubation of fenofibrate in whole blood caused hydrolysis of the ester bond with the release of fenofibric acid.

show abstract

Section: Introductionmentioning

confidence: 99%

Fenofibrate and fenofibric acid analysis by capillary electrophoresis

Shihabi

2004

Electrophoresis

View full text Add to dashboard Cite

show abstract

“…Since 1999, numerous nonrandomized and randomized (placebo, active comparator) trials of fenofibrate have been published (Tables 2 [6,13,18,21,37,40,44,49,55,62,70] and 3 [2,3,12,14,16,17,25,28,30,32,39,42,43,45,48,51,58,61,66,68], respectively). The results in Table 2 mirror those obtained in the previously-published review (33), demonstrating significant reductions in TC, LDL-C, TG, apo-B, fibrinogen, uric acid, and serum insulin and increases in HDL-C and apo-AI during fenofibrate therapy as compared to baseline.…”

Section: Therapeutic Usementioning

confidence: 99%

“…Fenofibrate does not appear to affect left ventricular function at rest or during exercise (14). A recent comparative trial involving micronized fenofibrate, 200 mg once daily, and gemfibrozil, 900 mg once daily, demonstrated significantly greater effects of fenofibrate than of gemfibrozil on TC, LDL-C, and uric acid (39).…”

Section: Therapeutic Usementioning

confidence: 99%

Update on Fenofibrate

Guay

2002

Cardiovascular Drug Reviews

View full text Add to dashboard Cite

Fenofibrate is a fibric acid derivative that has been marketed since the mid-1970's (1998 in the United States). Its active metabolite, fenofibric acid, is responsible for the primary pharmacodynamic effects of the drug: reductions in total plasma cholesterol, lowdensity lipoprotein cholesterol, triglycerides, and very low-density lipoprotein concentrations and increases in high-density lipoprotein cholesterol and apolipoproteins AI and AII concentrations. These effects are mediated by activation of peroxisome proliferator-activated receptor-á (PPAR á ). The drug has broad spectrum utility, with documented efficacy in Fredrickson types IIa, IIb, III, IV, and V hyperlipidemias. Fenofibrate is well tolerated, with digestive and musculoskeletal side effects similar to those of other fibrates. Results of the initial cardiovascular morbidity/mortality outcomes study with fenofibrate (known as DAIS [Diabetes Atherosclerosis Intervention Study]) were encouraging vis-à-vis slowing of atherosclerotic progression in the coronary vasculature of type II diabetics. The results of other ongoing outcome trials are eagerly awaited. These results will help to establish the overall place of fenofibrate in the hypolipidemic armamentarium.

show abstract

“…Its ability to increase HDL-C in patients with hypertriglyceridemia is impressive, but minor changes occur in patients with low HDL-C and normal triglycerides (84). Fenofibrate may be slightly more effective than gemfibrozil in reducing LDL-C in patients with hypercholesterolemia or mixed hyperlipidemia (85,86). Despite mild to modest effects on LDL-C, both drugs cause a desirable shift in LDL particle size from small/ dense (pattern B) to large/buoyant (pattern A; Refs.…”

Section: Cholesterol Absorption Inhibitors [Ezetimibe (Zetia)]mentioning

confidence: 99%